Exchange Traded Concepts LLC Decreases Stake in CRISPR Therapeutics AG (NASDAQ:CRSP)

Exchange Traded Concepts LLC trimmed its holdings in shares of CRISPR Therapeutics AG (NASDAQ:CRSPFree Report) by 16.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 16,127 shares of the company’s stock after selling 3,065 shares during the quarter. Exchange Traded Concepts LLC’s holdings in CRISPR Therapeutics were worth $635,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of CRSP. Highline Wealth Partners LLC purchased a new position in shares of CRISPR Therapeutics during the 4th quarter valued at approximately $39,000. Wilmington Savings Fund Society FSB acquired a new stake in CRISPR Therapeutics in the third quarter valued at $40,000. Darwin Wealth Management LLC acquired a new stake in CRISPR Therapeutics in the third quarter valued at $43,000. Eastern Bank bought a new position in CRISPR Therapeutics during the 3rd quarter valued at $70,000. Finally, MCF Advisors LLC acquired a new position in CRISPR Therapeutics during the 4th quarter worth $80,000. Institutional investors and hedge funds own 69.20% of the company’s stock.

Insider Buying and Selling

In other news, CEO Samarth Kulkarni sold 15,000 shares of CRISPR Therapeutics stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $55.10, for a total transaction of $826,500.00. Following the transaction, the chief executive officer now owns 181,540 shares in the company, valued at approximately $10,002,854. The trade was a 7.63 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 4.10% of the company’s stock.

CRISPR Therapeutics Trading Up 2.0 %

Shares of CRISPR Therapeutics stock opened at $42.04 on Friday. The company’s 50-day moving average price is $43.88 and its two-hundred day moving average price is $47.38. The stock has a market cap of $3.59 billion, a PE ratio of -14.86 and a beta of 1.68. CRISPR Therapeutics AG has a 52 week low of $36.52 and a 52 week high of $91.10.

CRISPR Therapeutics (NASDAQ:CRSPGet Free Report) last issued its earnings results on Tuesday, November 5th. The company reported ($1.01) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.42) by $0.41. CRISPR Therapeutics had a negative net margin of 118.13% and a negative return on equity of 12.15%. The firm had revenue of $0.60 million during the quarter, compared to analysts’ expectations of $6.65 million. During the same period last year, the firm posted ($1.41) earnings per share. On average, equities analysts predict that CRISPR Therapeutics AG will post -5.13 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently commented on CRSP shares. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $53.00 price target on shares of CRISPR Therapeutics in a research report on Wednesday, November 6th. Barclays lowered their price target on CRISPR Therapeutics from $59.00 to $55.00 and set an “equal weight” rating for the company in a report on Wednesday, November 6th. Chardan Capital reaffirmed a “buy” rating and issued a $94.00 price objective on shares of CRISPR Therapeutics in a report on Tuesday, December 10th. Bank of America lowered their target price on CRISPR Therapeutics from $98.00 to $85.00 and set a “buy” rating for the company in a report on Tuesday, January 7th. Finally, JMP Securities restated a “market outperform” rating and set a $86.00 price target on shares of CRISPR Therapeutics in a research report on Friday, December 20th. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating and ten have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $78.38.

View Our Latest Research Report on CRISPR Therapeutics

About CRISPR Therapeutics

(Free Report)

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.

Recommended Stories

Institutional Ownership by Quarter for CRISPR Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for CRISPR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.